Ladenburg raised the firm’s price target on Avadel Pharmaceuticals to $22 from $21.50 and keeps a Buy rating on the shares following the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals reports Q2 EPS (14c), consensus (16c)
- AVDL Earnings this Week: How Will it Perform?
- Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8
- Avadel Pharmaceuticals Advances Idiopathic Hypersomnia Treatment
- Needham healthcare analysts hold analyst/industry conference call